Inventor · disambiguated record
David F. Carmichael
Also filed as: CARMICHAEL DAVID F
10 granted patents·10 pending applications·174 citations·filing 1994–2011
90Inventor score
Top patents by PatentIndex Score
20 records- 0196US9040041B2Modified FC moleculesDESJARLAIS JOHN R·Filed 2010·Granted May 26, 2015·35 cites·3 claims
- 0294US7662367B2Pharmaceutical compositions for the treatment of TNF-α related disordersXENCOR INC·Filed 2006·Granted Feb 16, 2010·30 cites·6 claims
- 0385US7973136B2Optimized anti-CD30 antibodiesXENCOR INC·Filed 2006·Granted Jul 5, 2011·7 cites·8 claims
- 0482US9574006B2Optimized anti-CD30 antibodiesLAZAR GREGORY ALAN·Filed 2011·Granted Feb 21, 2017·5 cites·9 claims
- 0576US6358741B1Connective tissue growth factor (CTGF) and methods of useFIBROGEN INC·Filed 1999·Granted Mar 19, 2002·40 cites·16 claims
- 0675US6555322B1α2-macroglobulin receptor as a receptor for CTGFFIBROGEN INC·Filed 2000·Granted Apr 29, 2003·6 cites·7 claims
- 0774US6159460AMethod for treating interleukin-1 mediated diseasesAMGEN INC·Filed 1994·Granted Dec 12, 2000·46 cites·19 claims
- 0867US6800732B2Human collagenase inhibitor, recombinant vector system for using same and recombinant DNA method for the manufacture of sameAMGEN INC·Filed 2001·Granted Oct 5, 2004·3 cites·1 claims
- 0965US2007166309A1Optimized anti-cd30 antibodiesXENCOR INC·Filed 2007·Application pending·0 cites
- 1064US2007148171A1Optimized anti-CD30 antibodiesXENCOR INC·Filed 2006·Application pending·0 cites
- 1161US2008206867A1Fc variants with optimized Fc receptor binding propertiesDESJARLAIS JOHN R·Filed 2007·Application pending·0 cites
- 1258US2007148170A1Fc Variants With Optimized Fc Receptor Binding PropertiesDESJARLAIS JOHN R·Filed 2006·Application pending·0 cites
- 1355US2007172449A1TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERSXENCOR INC·Filed 2006·Application pending·0 cites
- 1446US2007275460A1Fc Variants With Optimized Fc Receptor Binding PropertiesXENCOR INC·Filed 2006·Application pending·0 cites
- 1546US2002028847A1Method for treatment of fibrosis related diseases by the administration of prostacyclin derivativesFIBROGEN INC·Filed 2001·Application pending·0 cites
- 1637US2002142353A1Connective tissue growth factor (CTGF) and methods of useFIBROGEN INC·Filed 2002·Application pending·0 cites
- 1734US6342374B1Human collagenase inhibitor, recombinant vector system for using same and recombinant-DNA method for the manufacture of sameAMGEN INC·Filed 1999·Granted Jan 29, 2002·1 cites·4 claims
- 1834US2010222272A1Pharmaceutical Compositions for the Treatment of TNF-Alpha Related DisordersXENCOR INC·Filed 2010·Application pending·0 cites
- 1933US6090585AHuman collagenase inhibitor sequence, recombinant vector system for using same and recombinant-DNA method for the manufacture of sameAMGEN INC·Filed 1995·Granted Jul 18, 2000·1 cites·8 claims
- 2020US2001006979A1Method for treatment of fibrosis related diseases by the administration of prostacyclin derivativesFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David F. Carmichael files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →